An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06532344 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: ONO-7913
DRUG: ONO-4538
DRUG: Oxaliplatin
DRUG: Levofolinate
DRUG: Irinotecan
DRUG: Fluorouracil

Sponsor

Ono Pharmaceutical Co., Ltd.